Recent estimates indicate that tuberculosis (TB) is the leading cause of death worldwide,
alongside the human immunodeficiency virus (HIV) infection. The current treatment is …

The repurposing of drug delivery by the pulmonary route has been applied to treatment and
prophylaxis of an increasingly wide range of respiratory diseases. Repurposing has been …

Acute infections caused by pathogenic bacteria have been studied extensively for well over
100 years. These infections killed millions of people in previous centuries, but they have …

The theranostic approach to local tuberculosis treatment allows drug delivery and imaging of
the lungs for a better control and personalization of antibiotic therapy. Metal-organic …

Tuberculosis (TB) is an intracellular infectious disease caused by the airborne bacterium,
Mycobacterium tuberculosis. Despite considerable research efforts, the treatment of TB …

Tuberculosis (TB) is a major global health burden. The emergence of the human
immunodeficiency virus (HIV) epidemic and drug resistance has complicated global TB …

Tuberculosis is the second leading cause of death from infectious diseases. Although
antitubercular drugs have been traditionally administered orally, there is a growing interest …

Inhalable microparticle-based drug delivery platforms are being investigated extensively for
Tuberculosis (TB) treatment as they offer efficient deposition in lungs and improved …

Despite the potent clinical efficacy of linezolid (LNZ) against drug-resistant tuberculosis, its
safety and tolerability remain of major concern. Our objective is to develop antitubercular …

Background: Tuberculosis (TB) ranks alongside the human immunodeficiency virus (HIV) as
cause of death due to an infectious disease. Recently, host-targeted therapies (HDT) have …